. Author manuscript; available in PMC: 2016 Nov 1.

Published in final edited form as: J Pain. 2015 Aug 18;16(11):1077–1086. doi: 10.1016/j.jpain.2015.07.005

Table 1.

Demographics and characteristics of the study participants

Participant Characteristics			P	Low pain hospitalization group (≤2 hospitalizations for pain in preceding 12 months) (n=14)	High pain hospitalization group (≥3 hospitalizations for pain in preceding 12 months) (n=8)
Median age (range) in years			0.33	17 (12–20)	18.5 (13–22)
Gender	Females, n (%)		0.60	9 (64%)	6 (75%)
Laboratory Parameters	Hemoglobin, (g/dL)		0.54	9.26 (±1.2)	8.83 (±1.7)
	Absolute Reticulocyte count, (k/mcL)		0.73	320 (±170)	288 (±231)
	Hemoglobin F, (%)		0.007	12.3 (±9.8)	3.8 (±2.3)
	MCV (fL) (only in patients prescribed hydroxyurea)		0.23	93.7 (± 10.8)	84.9 (±10.8)
Disease modifying therapy	Hydroxyurea	n (%)	0.74	8 (57%)	4 (50%)
	Hydroxyurea	Dose (mg/Kg/day)	0.25	23 (±3.1)	27 (±5.5)
	Chronic red cell transfusion, n (%)		0.24	5 (35%)	1 (12%)
Number of health care utilization visits for pain in preceding 12 months	Visits to the emergency department; median (range)		0.028	0 (0–1)	1.5 (1–7)
	Hospitalizations; median (range)		0.0001	0 (0–2)	8 (3–11)

All values are in mean ±SD unless specified otherwise